利用分泌型高斯荧光素酶的血液检测法监测肿瘤转移。

Blood-based assay with secreted Gaussia luciferase to monitor tumor metastasis.

作者信息

Yamashita Hiroshi, Nguyen Dan T, Chung Euiheon

机构信息

Department of Medical System Engineering and School of Mechatronics, Gwangju Institute of Science and Technology, Gwangju, South Korea.

出版信息

Methods Mol Biol. 2014;1098:145-51. doi: 10.1007/978-1-62703-718-1_12.

DOI:10.1007/978-1-62703-718-1_12

PMID:24166375

Abstract

Only a few techniques are currently available for quantifying systemic metastases in preclinical models. Cancer cell expression of naturally secreted Gaussia luciferase (Gluc) provides a useful circulating biomarker that enables the monitoring of metastatic tumor burden and of treatment response from minimal drops of blood. This blood-based Gluc assay exhibits several distinct advantages: (1) It is highly sensitive in quantifying metastatic tumor growth, particularly when compared to whole-body bioluminescence imaging (BLI) alone; (2) It is quantitative by nature and reflects viable tumor burden in a minimally invasive manner; (3) Through longitudinal collection of blood samples, treatment response can be monitored in real-time; and (4) Gluc bioluminescence provides a means to localize and assess metastatic colonization using BLI. By elucidating the progression of systemic metastases and therapeutic response in animal models, the blood-based Gluc assay is emerging as a valuable quantitative tool for novel drug development.

摘要

目前在临床前模型中，仅有少数技术可用于定量全身转移。癌细胞表达自然分泌的高斯荧光素酶（Gluc）可提供一种有用的循环生物标志物，能够通过极少量血样监测转移性肿瘤负荷及治疗反应。这种基于血液的Gluc检测具有几个明显优势：（1）在定量转移性肿瘤生长方面高度灵敏，尤其是与单独的全身生物发光成像（BLI）相比；（2）本质上是定量的，以微创方式反映存活肿瘤负荷；（3）通过纵向采集血样，可实时监测治疗反应；（4）Gluc生物发光提供了一种利用BLI定位和评估转移性定植的方法。通过阐明动物模型中全身转移的进展和治疗反应，基于血液的Gluc检测正成为新型药物研发的一种有价值的定量工具。